As dendritic cells (DCs) have pre-eminent responsibility for inducing T cell-mediated immunity, the targeting of vaccines to DCs in vivo is intuitively obvious in the setting of cancer. Heat shock protein hsp70 (hsp70) binds to both antigen (Ag)-uptake and signalingreceptors on DCs and may serve as a DC targeting molecule capable of improving the efficacy of vaccines. The longevity of activated Ag-bearing DCs in lymphoid tissues is also an important issue germane to the induction of specific immunity. Prolonging Ag-bearing DC survival in vivo may potentiate the potency of DNA vaccines. We have recently demonstrated that fusion proteins composed of tumor Ag and hsp70 (AghspTO) that are encoded in DNA vaccines induce significant anti-tumor immunity. Furthermore, the efficacy of these vaccines was augmented by prolonging DC survival via the delivery of the 'survival gene'Bcl-xl. We hypothesize that: 1) the in vivo targeting of AghspTO to DCs stimulates DC activation and induces T cell- mediated immunity and 2) that the prolongation of Aghsp70-bearing DC survival greatly improves the magnitude and quality of Ag-specific-T cell responses, resulting in potent clinical benefit. To test this hypothesis, we will pursue three specific aims:
Specific Aim 1 : Test whether OVAhsp70 proteins activate DCs via combined TLR4/CD40 triggering and enhance DC Ag-presenting capacity via CD91/CD40/LOX-1 receptor-mediated Ag-uptake, resulting in the induction of potent OVA-specific-T cell responses;
Specific Aim 2 : Test whether strong and sustained OVA-specific-T cell responses can be induced by the in vivo prolongation of OVAhsp70-bearing DC survival resulting from DNA vaccination;
Specific Aim 3 : Evaluate the efficacy of anti-tumor immunity induced by the In Vivo Targeted Vaccines. Experimental results obtained from these studies will be important in helping to optimize future tumor vaccine designs and provide additional insight into DC immunobiology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA108813-05
Application #
7760156
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Welch, Anthony R
Project Start
2006-03-01
Project End
2011-07-31
Budget Start
2010-02-01
Budget End
2011-07-31
Support Year
5
Fiscal Year
2010
Total Cost
$278,672
Indirect Cost
Name
University of Pittsburgh
Department
Dermatology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Zhang, Yi; Chen, Guo; Liu, Zuqiang et al. (2015) Genetic vaccines to potentiate the effective CD103+ dendritic cell-mediated cross-priming of antitumor immunity. J Immunol 194:5937-47
Tian, Shenghe; Liu, Zuqiang; Donahue, Cara et al. (2012) Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity. Mol Ther 20:432-42
Liu, Zuqiang; Falo Jr, Louis D; You, Zhaoyang (2011) Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity. J Immunol 187:118-25
Tian, S; Liu, Z; Donahue, C et al. (2009) Transcriptional IL-15-directed in vivo DC targeting DNA vaccine. Gene Ther 16:1260-70
Liu, Zuqiang; Kim, Jin H; Falo Jr, Louis D et al. (2009) Tumor regulatory T cells potently abrogate antitumor immunity. J Immunol 182:6160-7
Liu, Zuqiang; Tian, Shenghe; Falo Jr, Louis D et al. (2009) Therapeutic immunity by adoptive tumor-primed CD4(+) T-cell transfer in combination with in vivo GITR ligation. Mol Ther 17:1274-81
Liu, Zuqiang; Noh, Hae S; Chen, Janet et al. (2008) Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells. J Immunol 181:4363-70